Cell line · CVCL_1844
OCI-AML-3
Cancer cell line, Homo sapiens. Adult acute myelomonocytic leukemia. 84 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Cite this record
ConductScience Library. OCI-AML-3. Cell lines, record CVCL_1844. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1844
On this page
Cell line
As Cellosaurus gives it.
- Name
- OCI-AML-3
- Accession
- CVCL_1844
- RRID
- RRID:CVCL_1844
- Synonyms
- OCI-Aml-3, OCI/AML-3, OCI-AML3, OCI/AML3, OCI AML3, OCIAML3, Ontario Cancer Institute-Acute Myeloid Leukemia-3
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 57Y
- Category
- Cancer cell line
- Diseases
- Adult acute myelomonocytic leukemia (NCIt C7962); Acute myelomonocytic leukemia (ORDO Orphanet_517)
- Derived from
- Peripheral blood (in situ)
- Entry created
- 2012-04-04
- Entry updated
- 2026-06-25
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers84
2 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| BCLAF1 links RNA splicing to ATF4-dependent metabolic adaptation in acute myeloid leukemia. | Sci Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Extracellular vesicle-delivered siRNA targeting RCN1 suppresses acute myeloid leukemia through TFAM-dependent mtDNA-cGAS-STING signaling. | Extracell Vesicles Circ Nucl Acids | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Functional-genomic prioritization identifies MED12 as a candidate RNAi vulnerability in acute myeloid leukemia: evaluation of a T22 peptide-functionalized LNP-siRNA formulation. | Front Pharmacol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Greatwall kinase regulates acute myeloid leukaemia cell division through a non-canonical mechanism. | EMBO Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Novel noscapine derivative induces AML differentiation by dual-engaging DHODH and mitochondrial lipids to trigger a metabolic-epigenetic-transcriptional cascade. | Acta Pharm Sin B | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A structure-based modeling approach identifies effective drug combinations for RAS-mutant acute myeloid leukemia. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II. | Leukemia | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting SMC3 deacetylation synergizes with XPO1 inhibition to reprogram the epigenetic landscape and suppress NPM1-mutated acute myeloid leukemia. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| LDLRAD2 drives glycolysis and angiogenesis to promote extramedullary infiltration in acute myeloid leukemia. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Base Editing of TIGIT Reprograms CD155 Signaling in Natural Killer Cells to Enhance Cancer Immunotherapy Efficacy. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 84
See all 84 papersRelatives7
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | EDITGENE ASXL1 Knockout OCI-AML3 Cell Line | CVCL_F5IN | Cell lines | |
| Derived from it | EDITGENE OCI-Aml-3-CopGFP | CVCL_F6CI | Cell lines | |
| Derived from it | EDITGENE OCI-Aml-3-FLUC | CVCL_F5V1 | Cell lines | |
| Derived from it | HyCyte OCI-AML3 KO-hFGL2 | CVCL_D6C9 | Cell lines | |
| Derived from it | OCI-AML3/HaABCG2 clone 3.3 | CVCL_D6NG | Cell lines | |
| Derived from it | OCI-AML3/HaABCG2 clone 6.2 | CVCL_5227 | Cell lines | |
| Derived from it | OCI-AML3DNR | CVCL_D6NF | Cell lines |
Cell banks5
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| CCTCC | GDC0216 | Cellosaurus | |
| DSMZ | ACC-582 | DSMZ | |
| EDITGENE | EDC00313 | EDITGENE | |
| Hysigen | TCH-C384 | Hysigen | |
| Ubigene | YC-C022 | Ubigene |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1844
GET https://conductscience.org/api/cell-lines/v1/CVCL_1844/papers?page=2